An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22-75
SponsorErchonia Corporation
About this trial
The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.
Eligibility criteria
Qualifiers
Subject has voluntarily signed a written informed consent form.
Male or female 22 to 75 years of age, inclusive.
Subject has no evidence of Localized Aggressive Periodontitis.
Tooth loss due to periodontitis of ≤ 4 teeth.
Disqualifiers
Gingival recession which may be genetic, induced secondary to orthodontic treatment, induced secondary to frenulum attachments, or present as a result of dental malocclusion.
History of oral cancer or HIV in the last 6 months
Pregnant or intending to become pregnant in the next 8 months.
Sensitivity to, or contraindication for, light therapy.
Trial design
Treatments tested in this trial
- Erchonia® FX405
- Placebo Laser
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov